Alastair Greystoke, PhD, MBChB, PhD, MRCP, University of Newcastle & Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, describes the current state of biomarker testing in the UK and approaches to improve testing. Increased testing is required for patients to access suitable treatment, and Genomic Laboratory Hubs (GLHs) have aimed to offer genetic panel testing to patients throughout the UK. Prof. Greystoke additionally highlights how streamlining testing timelines is important for patients to receive treatment in a timely manner. This interview took place at the 20th Annual British Thoracic Oncology Group (BTOG) Conference 2022.